ARS制药公司击败了收入预测,使其股票飞涨;公司开发无针肾上腺素鼻涕喷剂。 ARS Pharmaceuticals beat earnings forecasts, sending its stock soaring; company develops a needle-free epinephrine nasal spray.

ARS制药公司报告,每股收入为0.52美元,比分析师的预期多出0.61美元。 ARS Pharmaceuticals reported earnings of $0.52 per share, exceeding analysts' expectations by $0.61. 库存激增至14.47美元,增加了2.82美元。 The stock surged to $14.47, up $2.82. 该公司正在开发一种无针的上腺素鼻喷雾剂,用于严重的过敏反应. The company is developing a needle-free epinephrine nasal spray for severe allergic reactions. ARS 的市值为 14.1 亿美元，市盈率为 -29.07，贝塔系数为 1.03。 ARS has a market cap of $1.41 billion, a PE ratio of -29.07, and a beta of 1.03. 它有一个共识的“Buy”评级和31.00美元的价格目标。 It has a consensus "Buy" rating and a $31.00 price target. Laura Shawver局长最近出售了相当大一部分股份 Director Laura Shawver recently sold a significant portion of her shares.